Resverlogix Thinks RVX-208 Can Succeed At Reducing Arterial Plaque Where Pfizer's Torcetrapib Failed

Resverlogix believes its small-molecule drug RVX-208 delivers on a key goal in cardiovascular drug development - the ability to clear life-threatening plaque out of arteries - setting the firm up to succeed with its first-in-class agent where others have failed and to write its own ticket in the $35 billion cholesterol market